|
Volumn 363, Issue 22, 2010, Pages 2171-2174
|
Retinopathy progression in type 2 diabetes [4]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
DIABETIC MICROANGIOPATHY;
DIABETIC PATIENT;
DIABETIC RETINOPATHY;
DYSLIPIDEMIA;
GLYCEMIC CONTROL;
HUMAN;
LETTER;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PRIORITY JOURNAL;
RISK REDUCTION;
DISEASE COURSE;
DRUG ANTAGONISM;
HYPERTENSION;
HYPOTENSION;
NOTE;
CARDIOVASCULAR DISEASE;
RISK FACTOR;
BLOOD PRESSURE REGULATION;
DISEASE SEVERITY;
DRUG EFFICACY;
NONHUMAN;
VISUAL IMPAIRMENT;
ANTILIPEMIC AGENT;
FENOFIBRATE;
VASCULOTROPIN A;
ANTIDIABETIC AGENT;
VASCULOTROPIN;
VASCULOTROPIN RECEPTOR 2;
DIABETES MELLITUS, TYPE 2;
DIABETIC RETINOPATHY;
DISEASE PROGRESSION;
FENOFIBRATE;
HUMANS;
HYPERTENSION;
HYPOLIPIDEMIC AGENTS;
HYPOTENSION;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
CARDIOVASCULAR DISEASES;
HYPOGLYCEMIC AGENTS;
RISK FACTORS;
|
EID: 78649407834
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc1009236 Document Type: Letter |
Times cited : (13)
|
References (4)
|